Micron Biotech: The company currently does not have an Ebola Zaire detection kit.

Gelonghui, May 22 | Maike Bio stated on an interactive platform that the company currently does not have an Ebola Zaire detection kit. The company will continue to monitor testing demand for relevant pathogens and dynamically assess potential R&D projects.

Gelonghui FinanceMay 22 12:38

MicroPort Bio (300463.SZ): New product obtains product registration certificate.

Gelonghui, May 14 — MicroPort Bio (300463.SZ) announced that it has recently received the "Medical Device Registration Certificate" (for in vitro diagnostic reagents) issued by the Sichuan Provincial Drug Administration. The product name is "Blood Gas Analysis Kit (Electrode Method)." This kit represents a new addition to the company's blood gas analysis platform and is primarily intended for auxiliary diagnosis in patients presenting with respiratory dysfunction, acid–base imbalance, hypoxia, carbon dioxide retention, electrolyte abnormalities, diabetes, hyperlactatemia, anemia, and other related conditions. Obtaining registration for this new product further expands the company's product portfolio, helping to enhance its overall market competitiveness, and will…

Gelonghui FinanceMay 14 17:38

A-share market movement | The Hantavirus outbreak draws attention! The virus prevention and treatment sector collectively surged, with Wantai Biotech up 9% and BGI Genomics rising over 5%.

Gelonghui, May 11 | Virus prevention and control concept stocks collectively rose in the A-share market. Among them, Walvax Biotech surged 19%, Capricorn Bio-Tech increased by over 15%, Daan Gene hit a 10% price limit, Wantai BioPharm gained 9%, Kangtai Biological Products rose over 8%, Zhifei Biological Products climbed 7%, and Frontier Biopharma-U, Probiotics Pharmaceuticals, CanSino Biologics, Wondfo Biotech, and Kanghua Biological Products increased by over 6%. Additionally, Jindike Biologics, BGI Group, Sichuan Maik Biotechnology, and TopRim Pharmaceuticals saw gains exceeding 5%. In terms of news, the cruise ship 'Hondeus' recently reported an outbreak of Hantavirus. Furthermore, a fatal case of Hantavirus was reported in Taipei City, Taiwan, related to infections carried by rats, drawing significant public attention.

Gelonghui FinanceMay 11 13:35

Maike Bio (300463.SZ): It is expected that the company's performance will show a relatively significant growth trend between 2027 and 2028.

Gelonghui, May 9th丨Maik Biology (300463.SZ) stated at the investor relations event that 2026 will be a crucial year for recovery following adjustments. In the short term, industry policies and the company’s strategic investments will continue to exert pressure on profit margins in the first half and potentially throughout 2026. The Q1 performance indicates a bottoming-out trend for the full year. As smart laboratories stabilize operations and certain influencing factors gradually diminish, operational pressures are expected to ease quarter by quarter. It is anticipated that revenue growth from proprietary products may turn positive for the full year. The scaled operational outcomes of the company’s smart laboratories and assembly line installations...

Gelonghui FinanceMay 9 14:43

Maik Biology (300463.SZ): The company's target of adding over 100 new signed clients for the entire year remains unchanged.

Gelonghui, May 9th | Maike Bio (300463.SZ) stated during an investor relations event that regarding the progress of its intelligent laboratory solutions, the company has set annual sales budget targets and medium- to long-term market objectives. By the end of Q1 2026, the cumulative contract target exceeds 100 clients, with actual execution resulting in contracts signed with a cumulative total of 70 clients, including approximately 14 new contracts signed in Q1. Despite the ongoing impact of industry reforms such as DRG/DIP payment systems and centralized procurement policies, which have extended the procurement decision-making cycle for medical institutions, under the current industry conditions, the company achieved 14 new contracts in Q1, bringing the cumulative total close to 70.

Gelonghui FinanceMay 9 14:41

Maike Biotechnology (300463): Business Transformation Expected to Drive New Growth Momentum

The company reported revenue/parent net profit/non-parent net profit of RMB 2.17 billion/RMB -36 million/RMB 17 million (yoy-14.8%/turned to loss/yoy-87.5%) in the 25-year period, which was in line with the earnings forecast (forecasted revenue of RMB 2.1 billion).

Huatai SecuritiesApr 30 16:51